

REMARKS

After entering these amendments, Claims 1 and 3-9 will be pending. Claims 1, 3 and 8 have been amended. Claim 2 has been canceled.

THE REJECTIONS UNDER 35 U.S.C. §112:

Claims 8 and 9 were rejected under 35 U.S.C §112, first paragraph, “because the specification while being enabling for treating breast cancer and prostate cancer, does not reasonably provide enablement for treating all diseases embraced in the claim 8.” (June 28, 2006 Office Action, Page 2). Applicants traverse. Applicants appreciate the Examiner’s statement that the claims are enabled “for treating breast cancer and prostate cancer.” (June 28, 2006 Office Action, Page 2). Applicants contend that the specification as originally filed also enables the use of the compounds defined in Claim 1 to be used to treat or delay the progression or onset of frailty or age-related functional decline. (Page 2, lines 8-17 of the specification as originally filed). Claim 8 has been amended to recite “[a] method for treating or delaying the progression or onset of frailty or age-related functional decline and prostate cancer, which comprises . . .” Applicants, therefore, respectfully request the Examiner withdraw this rejection as it is now moot.

THE REJECTIONS UNDER 35 U.S.C. §102:

Claims 1 and 5-9 were rejected under 35 U.S.C. §102(b) as anticipated by WO 02/18335 (hereinafter “Morihira”). (June 28, 2006 Office Action, Page 7). Applicants respectfully traverse.

Applicants have amended Claim 1 to incorporate the definition of variable G from Claim 2 into Claim 1. Claim 2 was not rejected over Morihira. Applicants respectfully request the Examiner withdraw this rejection as it is now moot.

THE REJECTIONS UNDER 35 U.S.C. §103:

Claims 1 and 5-9 were rejected under 35 U.S.C. §103(a) “as being unpatentable over Morihira et al., WO 02/18335.” (June 28, 2006 Office Action, Page 7). Applicants respectfully traverse.

Applicants have amended Claim 1 to incorporate the definition of variable G from Claim 2 into Claim 1. Claim 2 was not rejected over Morihira. Applicants respectfully request the Examiner withdraw this rejection as it is now moot.

CONCLUSION

No fee is believed due for the filing of this Amendment; however, should any fee be found to be due please charge said fee to Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company. In view of the foregoing, applicants submit that the application is now in condition for allowance. Early notification of such action is earnestly solicited.

Respectfully submitted,



Sammy G. Duncan, Jr., Ph.D.
Attorney for Applicant
Reg. No. 46,675
Phone: 609-252-6270
Date: August 28, 2006

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000